SRT 1460 |
Catalog No.GC65019 |
SRT 1460, un puissant activateur de Sirtuine-1 (SIRT1) avec une valeur EC1.5 de 2,9 μM, montre une bonne sélectivité pour l'activation de SIRT1 par rapport À SIRT2 et SIRT3 (EC1.5> 300 μM), et est plus puissant que le resvératrol et le homologues les plus proches de la sirtuine.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 925432-73-1
Sample solution is provided at 25 µL, 10mM.
SRT 1460, a potent Sirtuin-1 (SIRT1) activator with an EC1.5 value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 μM), and is more potent than Resveratrol and the closest sirtuin homologues[1].
SRT 1460 (2-6 μM; 72 hours) inhibits cell viability in a dose-dependent manner, with all pancreatic cancer cells being more sensitive than the control HPDE cell. The IC50s of those cells are: Patu8988t, 1.62±0.13 μM; SU86.86, 2.31±0.23 μM; Panc-1, 0.66 ±0.02 μM; HPDE, 2.39±0.29 μM[2].SRT 1460 (5 μM; 16 hours) increases expression of the autophagy marker LC3-II[2].
[1]. Milne JC, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29; 450(7170): 712-716.
[2]. Chini CC, et al. SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res. 2016 May 15;22(10):2496-507.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *